AAP
LENZ

Arax Advisory Partners’s LENZ Therapeutics LENZ Stock Holding History

Arax Advisory Partners’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$238 Buy
+26
New +$365 ﹤0.01% 3516
2025
Q4 		– Sell
-55
Closed -$2.56K – 4586
2025
Q3 		$2.56K Buy
+55
New +$2.02K ﹤0.01% 3051
2024
Q4 		– Sell
-12
Closed -$285 – 2788
2024
Q3 		$285 Hold
12
– – ﹤0.01% 2479
2024
Q2 		$208 Buy
+12
New +$210 ﹤0.01% 2434

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Arax Advisory Partners's LENZ Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in LENZ Therapeutics (LENZ) in Q1 2026: 26 shares worth $238. The stake represents ﹤0.01% of the portfolio and ranks #3516 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in LENZ as recently as Q3 2025.

Arax Advisory Partners first reported a position in LENZ in Q2 2024 and has held it in 4 quarters since. The position peaked at $2.56K in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Arax Advisory Partners held 26 shares of LENZ Therapeutics worth $238 as of Q1 2026.
  • LENZ Therapeutics was a new Arax Advisory Partners position in Q1 2026.
  • LENZ Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3516 holding.
  • Arax Advisory Partners first reported a position in LENZ Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • Arax Advisory Partners's LENZ Therapeutics position peaked at $2.56K in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.